|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1050 K STREET, NW, #800 |
Address2 | |
| City | WASHINGTON |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | RESEARCH TRIANGLE PARK |
State | NC |
Zip Code | 27709 |
Country | USA |
|
5. Senate ID# 16293-12
|
||||||||
|
6. House ID# 314610000
|
||||||||
| TYPE OF REPORT | 8. Year | 2011 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Sarah J. Walsh, Vice President, Federal Government Relations Tax & Pharmaceuticals |
Date | 07/20/2011 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
HR 2112 Fiscal Year 2012 Agriculture Appropriations - provisions pertaining to Ryan White CARE Act, FDA funding
HR 1473 The Department of Defense and Full Year Continuing Appropriations Act - provisions pertaining to Ryan White CARE
Act, FDA funding
Fiscal Year 2012 Labor-HHS-Education Appropriations - FY 2012 HHS Budget Request; proposal relating to Vaccine Section 317 program, Ryan White CARE Act
PL 111-148, PL 111-152 Patient Protection and Affordable Care Act - FY 2011 Prevention and Public Health Fund; allocations for Vaccine Section 317 program and smoking cessation programs
HR 2190, S 1206Medicare Drug Savings ActMedicare drug rebates
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Del Giorno |
|
|
|
Sarah |
Walsh |
|
|
|
William |
Schuyler |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
S 23, HR 1249 America Invents Act - provisions related to supplemental examination, first inventor to file, best mode, and false
marking
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Del Giorno |
|
|
|
Sarah |
Walsh |
|
|
|
William |
Schuyler |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Stephen |
Scango |
|
Legislative Assistant, Rep. E. G. "Bud" Shuster |
|
Stephen |
Scango |
|
Legislative Assistant, Rep. Michael Castle |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
PL 111-148, PL 111-152 Patient Protection and Affordable Care Act - ACA implementation, Independent Payment Advisory Board (IPAB), comparative effectiveness, health information technology, disease prevention/wellness, sunshine and innovation provisions
HR 452 Medicare Decisions Accountability Act - repeal of Independent Payment Advisory Board (IPAB)
S 668 Health Care Bureaucrats Elimination Act - repeal of Independent Payment Advisory Board (IPAB)
HR 1930 Access to Appropriate Immunizations for Veterans Act of 2011- extending VA performance measures to include all
federally recommended vaccines
HR 2405 Pandemic and All Hazards Preparedness Act - Re-authorization; influenza vaccine innovative technologies
S 1002 Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act (SAFE DOSES)
drug safety
HR 1483 The Drug Safety Enhancement Act of 2011- drug safety standards
HR 2182 Generating Antibiotic Incentives Now Act of 2011Provisions related to antibiotics and incentives
ADDENDUM/General Lobbying Issue Area - Federal Food, Drug, and Cosmetic Act (currently unassigned) - section related to FDA and regulation of nicotine replacement therapies
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Del Giorno |
|
|
|
Sarah |
Walsh |
|
|
|
William |
Schuyler |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
PL 111-148, PL 111-152 Patient Protection and Affordable Care Act - Medicare and Medicaid payment, Medicare Part D coverage gap, 340B drug pricing, meaningful use
Part D benefit; quality measures; COPD maintenance treatment
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS),
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Del Giorno |
|
|
|
Sarah |
Walsh |
|
|
|
William |
Schuyler |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Lynda |
Bryant-Comstock |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
ADDENDUM/General Lobbying Issue Area - Prescription Drug User Fee Act PDUFA-V (currently unassigned) - issues related to reauthorization of the Prescription Drug User Fee Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Del Giorno |
|
|
|
Sarah |
Walsh |
|
|
|
William |
Schuyler |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
HR 942 American Research and Competitiveness Act - reauthorization of research and development tax credit
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Del Giorno |
|
|
|
Sarah |
Walsh |
|
|
|
William |
Schuyler |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOR
16. Specific lobbying issues
HR 5, S 218 Help Efficient, Accessible, Low-cost, Timely Healthcare Act - provisions relating to various medical malpractice and
civil justice reforms
HR 605, S 312 Patients Freedom to Choose Act - provisions relating to reimbursement of OTC drugs under flexible spending and
health savings accounts
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Del Giorno |
|
|
|
Sarah |
Walsh |
|
|
|
William |
Schuyler |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address | |
||||||
| City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
| City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |